JP2007510622A - B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 - Google Patents

B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 Download PDF

Info

Publication number
JP2007510622A
JP2007510622A JP2006534362A JP2006534362A JP2007510622A JP 2007510622 A JP2007510622 A JP 2007510622A JP 2006534362 A JP2006534362 A JP 2006534362A JP 2006534362 A JP2006534362 A JP 2006534362A JP 2007510622 A JP2007510622 A JP 2007510622A
Authority
JP
Japan
Prior art keywords
antibody
gene
vie
vib
vic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510622A5 (cg-RX-API-DMAC7.html
Inventor
メスマー、ブラッドリー・ティ
キオラッツィ、ニコラス
アルベシアーノ、エミリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Feinstein Institutes for Medical Research
Original Assignee
The Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Feinstein Institutes for Medical Research filed Critical The Feinstein Institutes for Medical Research
Publication of JP2007510622A publication Critical patent/JP2007510622A/ja
Publication of JP2007510622A5 publication Critical patent/JP2007510622A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006534362A 2003-10-08 2004-10-08 B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 Pending JP2007510622A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50947303P 2003-10-08 2003-10-08
PCT/US2004/033176 WO2005034733A2 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
JP2007510622A true JP2007510622A (ja) 2007-04-26
JP2007510622A5 JP2007510622A5 (cg-RX-API-DMAC7.html) 2007-11-22

Family

ID=34434984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534362A Pending JP2007510622A (ja) 2003-10-08 2004-10-08 B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物

Country Status (6)

Country Link
US (2) US8119340B2 (cg-RX-API-DMAC7.html)
EP (1) EP1678195A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007510622A (cg-RX-API-DMAC7.html)
AU (1) AU2004279441B2 (cg-RX-API-DMAC7.html)
CA (1) CA2541360A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005034733A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517260A (ja) * 2014-05-30 2017-06-29 アカデミア シニカAcademia Sinica Mage−a3ペプチド標的アプタマー及びその使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
EP3957653A1 (en) * 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
DE102012212025A1 (de) * 2012-07-10 2014-01-16 Osram Gmbh Leuchtmodul
EP2741084B1 (en) 2012-12-07 2020-01-22 AVA Lifescience GmbH Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL)
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたb型肝炎コアポリペプチド
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017023859A1 (en) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
US20170073397A1 (en) * 2015-08-24 2017-03-16 Medimmune, Llc MrkA Polypeptides, Antibodies, and Uses Thereof
AU2016319126A1 (en) 2015-09-10 2018-04-19 Affigen, Inc. Sequencing-directed selection of tumor theranostics
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
US10836810B2 (en) 2017-02-17 2020-11-17 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
CN109752548B (zh) * 2019-02-01 2022-05-06 广州金域医学检验中心有限公司 评估慢性淋巴细胞白血病预后的组合试剂及系统
US12378321B2 (en) 2019-03-08 2025-08-05 Memorial Sloan Kettering Cancer Center ADAM17 binding molecules and uses thereof
EP4013794A4 (en) 2019-08-12 2023-11-22 City of Hope ANTI-IL1RAP ANTIBODIES
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
EP4341289A1 (en) * 2021-05-18 2024-03-27 Christian-Albrechts-Universität zu Kiel Co-stimulatory multispecific antibodies
CN113461818B (zh) * 2021-06-30 2022-01-21 徐州医科大学 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法
AU2023231622A1 (en) * 2022-03-07 2024-09-26 Agenus Inc. Anti-ilt2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP2270049A3 (en) * 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010057332, Blood, (1998), 92, [10, Suppl.1 Pt.1−2], p.431a(Abstract#1784) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517260A (ja) * 2014-05-30 2017-06-29 アカデミア シニカAcademia Sinica Mage−a3ペプチド標的アプタマー及びその使用

Also Published As

Publication number Publication date
WO2005034733A2 (en) 2005-04-21
US20120141462A1 (en) 2012-06-07
AU2004279441A1 (en) 2005-04-21
EP1678195A2 (en) 2006-07-12
US20090117095A1 (en) 2009-05-07
AU2004279441B2 (en) 2010-07-01
EP1678195A4 (en) 2008-04-23
WO2005034733A3 (en) 2005-09-09
CA2541360A1 (en) 2005-04-21
US9745364B2 (en) 2017-08-29
US8119340B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
US9745364B2 (en) Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
Messmer et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia
Ghiotto et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia
Craig et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins
CN101668853B (zh) 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用
JP2018102299A (ja) 膀胱癌の処置および診断のための方法および組成物
WO2003026493A2 (en) Diagnosis and treatment of diseases caused by mutations in cd72
JP2007518399A (ja) 肺癌を診断および治療する組成物並びに方法
US10175244B2 (en) Dominant negative HSP110 mutant and its use in prognosing and treating cancers
Wang et al. B-cell receptor repertoire: recent advances in autoimmune diseases
US20250304721A1 (en) Methods for generating high affinity antibodies against fentanyl
JP2008527998A (ja) Nsclcの診断のためのgitr抗体
US7118912B2 (en) Methods and compositions for categorizing patients
US20140220679A1 (en) Methods and compositions for categorizing patients
He et al. VH3-21 B cells escape from a state of tolerance in rheumatoid arthritis and secrete rheumatoid factor
Roers et al. Single-cell PCR analysis of T helper cells in human lymph node germinal centers
CN121006619A (zh) 构建纳米抗体编码dna文库的方法及应用
JP2002514897A (ja) Lyst1およびlyst2の遺伝子組成物ならびに使用方法
Karp et al. Antigen stimulation in the development of chronic lymphocytic leukemia.
Pandey et al. Genetics of human immunoglobulins
EP4514952A1 (en) Terminal deoxynucleotidyl transferase antibodies and uses thereof
Pandey et al. TWO GENES–ONE POLYPEPTIDE CHAIN Rationale In 1958 Beadle and Tatum received the Nobel prize for work demonstrating the 1 gene-1 polypeptide hypothesis in Neurospora. By contrast, in 1965 Dreyer and Bennett concluded that the Ig polypeptide chain was encoded by two genes (2
WO2006078780A2 (en) Rdc1 antibodies for the diagnosis of nsclc
Neubauer et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated
Pruzanski et al. Variable region gene analysis of pathologic human autoantibodies to

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120918